Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase <scp>1 and 2</scp> trials in overweight or obese participants of <scp>A</scp> sian descent with or without type 2 diabetes

Abstract

Once-daily cotadutide was effective and well tolerated up to 300 μg in overweight Japanese patients with T2D. Further evaluation in Asian populations is warranted.